dc.contributor.author | GEDİKLİ, MUSTAFA ASIM | |
dc.contributor.author | TÜZÜN, Burak | |
dc.contributor.author | AKTAŞ, Ahmet | |
dc.contributor.author | SAYIN, Koray | |
dc.contributor.author | ATASEVEN, Hilmi | |
dc.date.accessioned | 2022-05-18T10:30:46Z | |
dc.date.available | 2022-05-18T10:30:46Z | |
dc.date.issued | 2021 | tr |
dc.identifier.uri | http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7073&category_id=171&option=com_virtuemart | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/13206 | |
dc.description.abstract | Abstract: BACKGROUND: SARS-CoV-2, which started in Wuhan and later affected the whole world, is the most important disease of the world today. Many ways to inhibit SARS-CoV-2 virus are sought to prevent the spread of this virus. Azithromycin and clarithromycin are considered for the treatment of the SARS-CoV-2 virus, which has a high similarity to previous colonic diseases.
AIM: We aimed to determine whether azithromycin and clarithromycin, the RNA-dependent RNA polymerase protein inhibitor used in the treatment of COVID-19, is effective against SARS Cov-2 in silico.
RESULTS AND CONCLUSION: The 503 analogues of azithromycin and clarithromycin were studied to target SARS-CoV-2 the RNA-dependent RNA polymerase protein inhibition. Maestro program was used to compare the inhibition activities of these analogues. A detailed comparison was made using the numerical value of many parameters obtained. ADME / T properties were then examined to determine the effects and reactions of analogues on human metabolism. In this study, the SARS-CoV2 virus is 6NUR and 6NUS, which is the RNA-dependent RNA polymerase protein. Among these proteins, the best inhibitor among the 503 analogues according to the docking score parameter was 9851445 with a great difference. This analogue was an analogue of azithromycin (Tab. 3, Fig. 6, Ref. 58). | tr |
dc.language.iso | eng | tr |
dc.relation.isversionof | DOI: 10.4149/BLL_2021_015 | tr |
dc.rights | info:eu-repo/semantics/openAccess | tr |
dc.subject | SARS-CoV-2, RNA-dependent RNA polymerase, Azithromycin, Clarithromycin, COVID19 | tr |
dc.title | Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? | tr |
dc.type | article | tr |
dc.relation.journal | Bratislava Medical Journal | tr |
dc.contributor.department | Tıp Fakültesi | tr |
dc.contributor.authorID | 0000-0002-3494-7935 | tr |
dc.identifier.volume | 122 | tr |
dc.identifier.issue | 2 | tr |
dc.identifier.endpage | 110 | tr |
dc.identifier.startpage | 101 | tr |
dc.relation.publicationcategory | Uluslararası Editör Denetimli Dergide Makale | tr |